DVT complete diagnostic approach resident survival guide: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) |
||
Line 32: | Line 32: | ||
---- | ---- | ||
''' | '''Elicit a detailed history:'''<br><br> | ||
❑ Previous episode of [[VTE]] | ❑ '''Risk factors'''<ref name="pmid12814980">{{cite journal| author=Anderson FA, Spencer FA| title=Risk factors for venous thromboembolism. | journal=Circulation | year= 2003 | volume= 107 | issue= 23 Suppl 1 | pages= I9-16 | pmid=12814980 | doi=10.1161/01.CIR.0000078469.07362.E6 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12814980 }} </ref><ref name="pmid18757870">{{cite journal| author=Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P et al.| title=Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). | journal=Eur Heart J | year= 2008 | volume= 29 | issue= 18 | pages= 2276-315 | pmid=18757870 | doi=10.1093/eurheartj/ehn310 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18757870 }} </ref> | ||
:❑ [[Chemotherapy]]<br> | |||
:❑ [[Chronic heart failure]]<br> | |||
:❑ [[Respiratory failure]]<br> | |||
:❑ [[Hormone replacement therapy]]<br> | |||
:❑ [[Cancer]]<br> | |||
:❑ [[Oral contraceptive pills]] <br> | |||
:❑ [[Stroke]] <br> | |||
:❑ [[Pregnancy]] <br> | |||
:❑ [[Postpartum]] <br> | |||
:❑ Prior history of [[VTE]] <br> | |||
:❑ [[Thrombophilia]] <br> | |||
:❑ Advanced [[age]] <br> | |||
:❑ [[Laparoscopic surgery]] <br> | |||
:❑ Prepartum <br> | |||
:❑ [[Obesity]] <br> | |||
:❑ [[Varicose veins]] | |||
❑ '''Triggers'''<ref name="pmid12814980">{{cite journal| author=Anderson FA, Spencer FA| title=Risk factors for venous thromboembolism. | journal=Circulation | year= 2003 | volume= 107 | issue= 23 Suppl 1 | pages= I9-16 | pmid=12814980 | doi=10.1161/01.CIR.0000078469.07362.E6 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12814980 }} </ref><ref name="pmid18757870">{{cite journal| author=Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P et al.| title=Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). | journal=Eur Heart J | year= 2008 | volume= 29 | issue= 18 | pages= 2276-315 | pmid=18757870 | doi=10.1093/eurheartj/ehn310 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18757870 }} </ref> | |||
:❑ [[Bone fracture]] ([[hip]] or [[leg]]) <br> | |||
:❑ [[Hip replacement surgery]]<br> | |||
:❑ Knee replacement surgery<br> | |||
:❑ [[General surgery|Major general surgery]]<br> | |||
:❑ [[Trauma|Significant trauma]]<br> | |||
:❑ [[Spinal cord injury]]<br> | |||
:❑ Athroscopic knee surgery<br> | |||
:❑ [[Central venous line]]s<br> | |||
:❑ [[Chemotherapy]]<br> | |||
:❑ Bed rest for more than 3 days <br> | |||
:❑ Prolonged car or air travel <br> | |||
:❑ [[Laparoscopic surgery]] <br> | |||
:❑ Prepartum <br> | |||
❑ '''Previous episode of [[VTE]]''' | |||
:❑ Age | :❑ Age | ||
:❑ Location | :❑ Location | ||
❑ Past medical history | ❑ '''Past medical history of diseases associated with hyperviscosity''' | ||
:❑ [[Atherosclerosis]] | :❑ [[Atherosclerosis]] | ||
:❑ [[Collagen vascular disease]] | :❑ [[Collagen vascular disease]] | ||
Line 42: | Line 73: | ||
:❑ [[Myeloproliferative disease]] | :❑ [[Myeloproliferative disease]] | ||
:❑ [[Nephrotic syndrome]] | :❑ [[Nephrotic syndrome]] | ||
❑ History of [[thrombophilia]] | :❑ [[Autoimmune diseases]] | ||
:❑ Factor V Leiden mutation | :❑[[Polycythemia vera]] | ||
:❑ Prothrombin gene mutation G20210A | :❑ [[Hyperhomocysteinemia]] | ||
:❑ Protein C or S deficiency | :❑ [[Paroxysmal nocturnal hemoglobinuria]] | ||
:❑ Antithrombin (AT) deficiency | :❑ [[Waldenstrom macroglobulinemia]] | ||
:❑ Antiphospholipid | :❑ [[Multiple myeloma]] | ||
❑ Abortion at second or third trimester of [[pregnancy]] (suggestive of an inherited [[thrombophilia]] or | ❑ '''History of [[thrombophilia]]''' | ||
❑ Drugs that may | :❑ [[Factor V Leiden mutation]] | ||
:❑ [[Prothrombin gene mutation G20210A]] | |||
:❑ [[Protein C]] or [[Protein S]] deficiency | |||
:❑ [[Antithrombin]] (AT) deficiency | |||
:❑ [[Antiphospholipid syndrome]] (APS) | |||
❑ '''Abortion''' | |||
:❑ [[Abortion]] at second or third trimester of [[pregnancy]] (suggestive of an inherited [[thrombophilia]] or APS) | |||
❑ '''Drugs that may increase the risk of VTE''' | |||
:❑ [[Hydralazine]] | :❑ [[Hydralazine]] | ||
:❑ [[Phenothiazine]] | :❑ [[Phenothiazine]] | ||
:❑ [[Procainamide]] | :❑ [[Procainamide]] | ||
:❑ [[Tamoxifen]] | |||
:❑ [[Bevacizumab]] | |||
:❑ [[Glucocorticoids]] | |||
❑ '''Family history (suggestive of [[inherited thrombophilia]])''' | |||
:❑ [[Deep vein thrombosis]] | |||
:❑ [[Pulmonary embolism]] | |||
:❑ Recurrent [[miscarriage]] | |||
❑ '''Social history''' | |||
:❑ Heavy [[cigarette smoking]] (>25 cigarettes per day) | |||
:❑ [[Intravenous drug use]] (if injected directly in [[femoral vein]]) | |||
:❑ [[Alcohol]] | |||
</div>}} | </div>}} | ||
{{familytree | | | | | | | |!| | | }} | {{familytree | | | | | | | |!| | | }} |
Revision as of 14:22, 5 June 2014
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[1]
Identify possible precipitating factors: Elicit a detailed history:
❑ Previous episode of VTE
❑ Past medical history of diseases associated with hyperviscosity
❑ History of thrombophilia
❑ Abortion
❑ Drugs that may increase the risk of VTE ❑ Family history (suggestive of inherited thrombophilia)
❑ Social history
| |||||||||||||||||||||||||||||
❑ Examine the patient: Extremities
❑ Homan's sign: tenderness upon dorsiflexion of the foot (not reliable)
| |||||||||||||||||||||||||||||
Consider alternative diagnoses: ❑ Muscle strain or muscle tear | |||||||||||||||||||||||||||||
Is the suspected DVT a first or a recurrent episode? | |||||||||||||||||||||||||||||
First suspected episode | Suspected recurrent episode | ||||||||||||||||||||||||||||
Low pretest probability (Click here for the diagnostic approach) | Moderate pretest probability (Click here for the diagnostic approach) | High pretest probability (Click here for the diagnostic approach) | |||||||||||||||||||||||||||
Initial Anticoagulation Choices (DVT)
❑ SC low molecular weight heparin (1st line)
- ❑ Enoxaparin 1.0 mg/kg every 12 hours OR 1.5 mg/kg once daily
- ❑ Tinzaparin 175 U/kg once daily
❑ SC fondaparinux (1st line)
- ❑ 5 mg once daily (if body weight <50 kg)
- ❑ 7.5 mg once daily (if body weight <50-100 kg)
- ❑ 10 mg once daily (if body weight >100 kg)
- ❑ 80 U/kg as bolus, followed by 18 U/kg/h, OR
- ❑ 70 U/kg as bolus, followed by 15 U/kg/h for stroke or cardiac patients[4]
- ❑ Adjust the dosages according to the aPTT
- ❑ 333 U/kg as bolus, followed by 250 U/kg[4]
Anticoagulation for VTE
Warfarin
- Begin with 10 mg warfarin for 2 days followed by dosing based on the INR
- Start at the 1st or 2nd day of the initial parenteral therapy
- Target INR is 2-3
- Monitor INR:
- If stable, repeat INR every 12 weeks
- If stable but one value 0.5 below or above the target range, continue the same dose and repeat INR within 1-2 weeks
- Avoid NSAIDs, COX2 selective NSAIDs and some antibiotics[4]
Heparin
IV-UFH
- 80 U/kg as bolus, followed by 18 U/kg/h
- 70 U/kg as bolus, followed by 15 U/kg/h for stroke or cardiac patients[4]
SC-UFH
- 333 U/kg as bolus, followed by 250 U/kg[4]
LMWH: decrease dose in renal insufficiency (Creatinine clearance < 30 mL/min)[4]
Fondaparinux
- 7.5 mg daily
- 10 mg daily if weight>100 Kg[4]
- ↑ Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD; et al. (2012). "Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e351S–418S. doi:10.1378/chest.11-2299. PMC 3278048. PMID 22315267.
- ↑ 2.0 2.1 Anderson FA, Spencer FA (2003). "Risk factors for venous thromboembolism". Circulation. 107 (23 Suppl 1): I9–16. doi:10.1161/01.CIR.0000078469.07362.E6. PMID 12814980.
- ↑ 3.0 3.1 Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P; et al. (2008). "Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)". Eur Heart J. 29 (18): 2276–315. doi:10.1093/eurheartj/ehn310. PMID 18757870.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ; et al. (2012). "Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e152S–84S. doi:10.1378/chest.11-2295. PMC 3278055. PMID 22315259.